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specifically down-regulated TAB2 through a lysosomal pathway, and knockdown of RNF4 impaired
endogenous TAB2 degradation. Therefore, our findings will provide new insights into the negative
regulation of NF-jB signaling.
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The transcription factor NF-jB (nuclear factor kappa B) plays
pivotal roles in various cellular processes, such as inflammation,
innate immunity and cancer development [1–3]. In the resting
state, the transcription factor NF-jB is sequestered by NF-jB inhi-
bitor alpha (IjBa) in the cytoplasm and kept inactive. When cells
are under stimulation with proinflammatory cytokines, genotoxic
stresses and bacterial components, NF-jB inhibitor alpha (IjBa)
is phosphorylated and then degraded. NF-jB is released conse-
quently and translocates to nucleus where it activates expression
of NF-jB related genes [4,5].
Tumor necrosis factor alpha (TNFa) and interleukin 1 (IL-1) are
critical proinflammatory cytokines that could activate canonical
NF-jB signaling pathway respectively. There are many similarities
between TNFa and IL-1-induced NF-jB signaling pathways. In the
receptors stages of both signaling pathways, TNFa and IL-1 binddifferent receptors (TNFR1 or IL-1RI) and then recruit different
adaptor proteins to form receptor complexes [2,6]. Downstream
of formation of TNFR complex and IL-1R complex, the signal trans-
fer modes are nearly the same. TGF-b-activated kinase 1 (TAK1) are
recruited to TRAF2 (in TNF pathway) or TRAF6 (in IL-1 pathway) in
a form of TAK1–TAK1-binding protein2 (TAB2) and TAB3 complex,
resulting in the activation of IKKs, which phosphorylate IjB
proteins and lead to NF-jB activation [7,8].
However, many studies have shown that chronic inflammatory,
autoimmune disease and cancer development are closely associ-
ated with excessive activation of NF-jB signaling pathway. So,
the precise regulation of NF-jB signaling pathway is indispensable
and the negative regulation of NF-jB signaling pathway is still an
important issue. Until now, in canonical NF-jB signaling pathway,
several negative regulators have been discovered. TNFa-induced
protein 3 (TNFAIP3), also called A20, negatively regulates NF-jB
activity by deubiquitinating K63-linked polyubiquitinated RIP1
[9]. Another protein, ubiquitin carboxyl-terminal hydrolase CYLD,
deubiquitinates TRAF2 to block NF-jB activation [10]. CUE
domain-containing protein 2 (CUEDC2) regulates IKK dephospho-
rylation by recruiting PP1 to inhibit NF-jB activity [11]. It has also
been reported that UBX family protein UBXN1 could negatively
regulate NF-jB activity by competitively binding cIAPs to inhibit
RIP1 ubiquitination [12].
RING finer protein 4 (RNF4) was discovered as a special ubiqui-
tin ligase which was defined SUMO-targeted ubiquitin ligases. In
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RARalpha degradation in acute promyelocytic leukemia (APL)
[13–15]. In 2009, RNF4 was found to mediate PARP1 degradation
upon heat shock [16]. And in 2012, it was reported that RNF4
was involved in DNA double strand break repair by mediating
MDC1 degradation [17–19]. In this study, we constructed a siRNA
library against 203 genes which contain ubiquitin-related
domains. We used this library to screen regulators of canonical
NF-jB signaling pathway and identified RNF4 as an inhibitor of
both TNFa and IL-1b-induced NF-jB activation. Overexpression
of RNF4 caused down-regulation of TAB2 and inhibited canonical
NF-jB activation; whereas, knockdown of RNF4 potentiated IL-
1b-induced NF-jB activation. RNF4 interacted with and mediated
TAB2 lysosomal degradation. Our findings reveal a negative regula-
tory mechanism on the control of canonical NF-jB pathways.
2. Materials and methods
2.1. Reagents and antibodies
Chicken anti-RNF4 was from Pro. Ronald T Hay. Mouse-TAB2
was from Pro. Hong-Bing Shu. Anti-Myc (SC-789), anti-IjBa (SC-
371) and anti-p53 (SC-126) were from Santa Cruz; Anti-phospho-
IKKa/b (Serl76/180) (2679), anti-phospho-IjBa (Ser32), anti-ERK
(9102) and anti-phospho-ERK (9106) were Cell Signaling Technol-
ogy; Anti-JNK (51-1570GR) was from BD; Anti-phospho-JNK1/2
(44682G) was from Invitrogen; Anti-tubulin (T5168) and anti-
FLAG (F1804) were from Sigma–Aldrich. Recombinant human
TNFa (210-TA-020) was from R&D System. Recombinant human
IL-1b was from Sigma Aldrich.
2.2. Constructs
pNF-jB-Luc, pRL-TK and mammalian expression plasmids for
RNF4, TRADD, TRAF2, Myd88, IRAK1, TAB1, NEMO, IKKb were from
our own lab. Mammalian expression plasmids for TAK1, TAB2 and
TAB3 were from Hong-Bing Shu.
2.3. Cell transfection and RNA interference
siRNA library was purchased from Dharmacon SMARTpool,
Thermo Scientific. Individual RNF4 siRNAs were purchased from
Invitrogen stealth siRNA. Non-targeted sequence was used as con-
trol for RNAi-related experiments.
RNF4 siRNA sequence: #1 50-CGACCCGAAACAGAGUUGCUA
GUAA-30; #2 50-CCACCAGUUGUUCUCAGGAACCUUA-30.
Plasmids were transfected by Lipofectamine 2000 (Invitrogen),
and cells were harvested between 24 and 48 h after transfection.
siRNAs from Invitrogen or Dharmacon were transfected by Lipofec-
tamine RNAiMax (Invitrogen).
2.4. Luciferase reporter assays
HEK293, andU2OS cells (1  105)were transfectedwith 0.1 lg of
the luciferase reporter pNF-jB-Luc (IjBa promoter) plus 0.01 lg of
the Renilla reporter pRL-TK, with various amounts of pcDNA3.0-
FLAG-RNF4 and empty vector or with siRNAs targeted RNF4 and
non-targeted siRNA. After being treated for 10 h with 10 ng/ml of
TNFa or IL-1b, transfected cells were collected. Luciferase assays
were performedusing a dual-specific luciferase assay kit (Promega).
2.5. Quantitative real-time PCR
U2OS cells were treated with TNFa, respectively. Cell pellets
were collected and RNA was extracted with TRIzol (Invitrogen).Diluted RNA was reverse-transcribed, and subjected to qPCR anal-
ysis to measure mRNA expression levels of NF-jB targeted genes.
Gene-specific primer sequences were as follow: TNFA: Forward
50-GCCGCATCGCCGTCTCCTAC-30, Reverse 50-CCTCAGCCCCCTCTGG
GGTC; IL-8: Forward 50-TCTGGCAACCCTAGTCTGCT-30, Reverse
50-AAACCAAGGCACAGTGGAAC-30.
2.6. Coimmunoprecipitation and immunoblot
For transient transfection and coimmunoprecipitation experi-
ments, HEK293T cells (1  106) transfected with various plasmids
were incubated for 24–36 h before analysis and then lysed with
1 mL M2 lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 10%
glycerol, 1% Triton X-100, 0.5 mM EDTA, 0.5 mM EGTA) containing
certain protease inhibitors. The cell lysate was incubated with anti-
Flag M2 Agarose Affinity gel (A2220, Sigma Aldrich) for 4 h. Beads
were washed three times with 1 ml of lysis buffer. The precipitates
were analyzed by standard immunoblot procedures. For endoge-
nous immunoprecipitation experiments, lysis buffer was prepared
as 20 mM Tris pH 7.4, 250 mM NaCl, 0.5% NP-40, 3 mM EDTA,
3 mM EGTA with protease inhibitors (2 mM dithiothreitol,
50 mM NaF, 40 mM b-glycerophosphate, 5 mM tetrasodium
pyrophosphate, 0.1 mM sodium vanadate, Roche protease inhibitor
cocktail). All other samples for immunoblotting assays were
prepared in M2 lysis buffer.
2.7. Graph drawing and tabulation
Graphs in Fig. 1B: We overlapped all our hits from the screen
with ‘‘BioGRID Protein–Protein Interaction database” (http://thebi-
ogrid.org/), and draw the graph with ‘‘Cytoscape”. Then we held all
low-throughput data containing ‘‘BioID, biochemical, fluorescent
resonance energy transfer, genetic interference, imaging tech-
nique, protein complementation assay, pull down, and X-ray crys-
tallography”, but abandon high-throughput data (Supplementary
file 1).
Table in Fig. 1B: We define one hit gene and all its interactors as
a gene group (Supplementary file 2). We search each gene group
with ‘‘The Database for Annotation, Visualization and Integrated
Discovery” (DAVID, http://david.abcc.ncifcrf.gov/) to annotate
these gene groups. Results of several groups exhibited some same
functional annotations. Annotations with which ‘‘Bonferroni” and
‘‘Benjamini” value <0.01 were considered to be chosen (Supple-
mentary file 3).
3. Results
3.1. siRNA screen against ubiquitin-related domain proteins identified
potential regulators of canonical NF-jB signaling pathway
Canonical NF-jB signaling pathway has been discovered for
nearly 30 years. During past decades, many important adaptors
and regulators have been carefully studied. Most importantly, var-
ious post-translational modifications have been reported in this
pathway, especially ubiquitination [7,8,20]. Although much is
understood about ubiquitinated molecules which are involved in
NF-jB signaling transduction and activation, the termination of
the NF-jB activation is still need to be elucidated. We tried to focus
on those proteins which are ubiquitinated in canonical NF-jB
pathway, and designed a siRNA library from Dharmacon SMART-
pool library against most ubiquitin-related domain proteins espe-
cially ubiquitin-binding domain, such as UBA, UIM domains, and
so on. Given that most NF-jB pathway molecules are associated
with ubiquitin, it is reasonable to expect that ubiquitin-related
protein that could turn off the pathway. 203 siRNA in this library
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Fig. 1. siRNA screen against ubiquitin-related domain proteins identify potential regulators of canonical NF-jB signaling pathway. (A) A screen with siRNA to 203 known
proteins containing ubiquitin-related domains was performed using Dharmacon siRNA library. Transfection of siRNAs into U2OS-NF-jB-luciferase reporter cells was
performed. The scatter plot shows background-subtracted luciferase values for each siRNA-treated sample, which had been induced with TNFa (10 ng/ml) for 12 h or IL-1b
(10 ng/ml) for 12 h. Each dot represents (normalized) intensity from one well of 13,000 U2OS cells. The average raw luciferase value of the screen was inferred and indicated
(Av). Values that were 1.5-fold higher or 1.5-fold lower than the average were marked by dotted lines. Shown here is a representative screen. Knockdown of RNF4 (marked in
red) reproducibly enhanced NF-jB activation by more than 1.5-fold upon either TNFa or IL-1b treatment. (B) Hits with their interactors network derived from BioGRID PPI
database (Left panel); each gene group was defined as one hit with its interactors. ‘‘The Database for Annotation, Visualization and Integrated Discovery” (DAVID, http://
www.david.abcc.ncifcrf.gov/) was used to annotate each gene group.
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NF-jB-luciferase cells, and reporter assay was performed after
TNFa and IL-1b stimuli. We found that knockdown of RNF4 acti-
vated NF-jB- dependent reporter 1.5-fold more than the average
in response to both TNFa and IL-1b (Fig. 1A), while knockdown
of A20 and RNF31 were positive controls as previous studies
reported [9,21].
We finally have 24 hits in TNFa pathway and 23 hits in IL-1b
pathway. Based on the latest PPI database of BioGRID (http://thebi-
ogrid.org/), we draw a PPI network of hits and their interactors
(Fig. 1B). We defined that one hit together with its interactors as
a gene group, and we intended to find in which cellular process
those groups are involved. We utilized functional annotation in
‘‘The Database for Annotation, Visualization and Integrated
Discovery” (DAVID, http://david.abcc.ncifcrf.gov/) to annotate
these gene groups. We found that those candidates of NF-jB
pathway could be classified into several categories, such as macro-
molecular complex assembly, DNA repair, vesicle-mediated trans-
port and so on (Fig. 1B). This analysis indicated that those cellular
processes might have crosstalk with NF-jB signaling pathway
through these candidate proteins.
3.2. Identification of RNF4 as a negative regulator of canonical NF-jB
signaling pathway
To further confirm that RNF4 regulates canonical NF-jB path-
way upon TNFa and IL-1b, we designed 2 other individual siRNAs
and repeated the reporter assay. Similar result was found that
knockdown of RNF4 potentiated TNFa- and IL-1b-induced NF-jB
activation dependent of the knockdown efficiency (Fig. 2A).
Consistent with these observations, Real-time Quantitative PCR
experiments demonstrated that knockdown of RNF4 potentiated
TNFa- and IL-1b-triggered transcription of endogenous TNFA and
IL-8 genes (Fig. 2B). Further, ELISA assay indicated that TNFa
production by knockdown of RNF4 in U2OS cells was also
up-regulated (Fig. 2C). Consistent with the knockdown assay, we
transiently overexpressed RNF4 in HEK293 cells and found that
RNF4 had obvious dose-dependent ability down-regulating TNFa-
and IL-1b-triggered NF-jB activation (Fig. 2D) but not poly
I:C-triggered activation of IFNp and ISRE reporter in HEK293-
TLR3 cells (Fig. 2E). These results suggest that RNF4 is a physiolog-
ical suppressor of canonical NF-jB signaling pathway.
3.3. RNF4 suppressed NF-jB signaling at TAK complex level
To further confirm at which level RNF4 negatively regulates NF-
jB signaling. We examined the effect of RNF4 on NF-jB activation
mediated by important adaptor proteins and kinases, TRADD,
TRAF2 in TNFa signaling pathway, Myd88, IRAK1 in IL-1b signaling
pathway, and TAK1 and IKKb in the downstream of both signaling
pathways. Overexpression of RNF4 markedly blocked the NF-jB
activation mediated by TRADD, TRAF2, Myd88, IRAK1 and TAK1in
reporter assay (Fig. 3A and B). In contrast, RNF4 did not affect IKKb
mediated NF-jB activation in reporter assay (Fig. 3A and B).
We next investigated whether RNF4 affected IKK activation in
NF-jB signaling. In response to TNFa treatment in U2OS cells,
phosphorylation of IKK was much more robust when RNF4 was
down-regulated by siRNA than when cells were transfected with
control siRNA (Fig. 3C). Specifically, silencing RNF4 expression
resulted in prolonged IKK activation and accelerated degradation
of IjBa (Fig. 3C). Activation of other MAPKs such as JNK and ERK
were also enhanced by RNF4 knockdown following TNFa
stimulation (Fig. S1A). Consistently, in response to TNFa treatment,
we barely detected phosphorylation of IKK in HEK293 cells trans-
fected with the RNF4 plasmid. In addition, overexpression of
RNF4 blocked TNFa-induced IjBa degradation (Fig. 3D). Theseresults indicated that RNF4 has an inhibitory effect on IKK activa-
tion, and may acts as a regulator at TAK complex level upstream of
IKK.
3.4. RNF4 interacted with TAK complex and down-regulated TAB2 level
To unambiguously identify potential NF-jB pathway proteins
associated with RNF4. We overexpressed Flag-vector, full length
Flag-RNF4 and Flag-RNF4-ASIM (SIM, SUMO interaction motif) in
HEK293T cells. We purified RNF4 and its associated proteins with
Flag beads and separated them by coomassie blue staining. The
separated gels were identified by a mass spectrometry analysis
(Fig. 4A). By comparing with purifications of Flag-Vector group
with the same method, we identified TAK1 as a candidate protein
associated with RNF4 and RNF4-ASIM. As TAK1 always plays its
role in a complex with TAB1/2 or TAB2/3, we investigated the
associations between TAK complex components and RNF4. We
performed transient transfection and co-immunoprecipitation
experiment in HEK293T cells. The result indicated that RNF4 inter-
acted with TAK1, TAB2 and TAB3 but not TAB1 in mammalian
overexpression system (Fig. 4B). In the previous studies, several
important substrates of RNF4 have been discovered, such as PML,
PARP1. RNF4 mediated PML and PARP1 degradation under certain
circumstances. To test whether RNF4 could destabilize NF-jB sig-
naling molecules, we co-overexpressed wild-type RNF4 and its E3
ligase activity deletion mutant RNF4-C132/135S with other
important NF-jB signaling molecules, TAK1, TAB1, TAB2, TRAF2,
TRAF6 and NEMO in HEK293T cells. The results showed that only
wild-type RNF4 destabilized exogenous TAB2 level but no other
NF-jB signaling molecules comparing exogenous GFP as a control
(Fig. 4C). As TAB3 was a homologous protein with TAB2, we also
found RNF4 could affect TAB3 stability (Fig. S1B). Therefore, we
detect whether RNF4 could interact with TAB2 under endogenous
condition. Endogenous immunoprecipitation experiment indicated
that TNFa stimulation induced endogenous interaction between
TAB2 and RNF4 (Fig. 4D). To confirm whether this phenomenon
is due to accelerated degradation of TAB2, we used Cycloheximide
(CHX) to block new TAB2 translation and synthesis. And the result
showed that RNF4 could still affect TAB2 stability (Fig. S1C). These
results suggested that RNF4 may inhibit NF-jB signaling by target-
ing TAB2 for degradation and inhibit NF-jB activation.
3.5. RNF4 mediated lysosome-dependent degradation of TAB2
In the previous reports, SUMO interaction motif of RNF4 facili-
tated its interaction with polysumoylated substrates and mediated
degradation of the substrates [19,22]. However, in our mammalian
overexpression system, both wild-type RNF4 and RNF4-ASIM could
destabilize TAB2, while overexpression of RNF4-C132/135S has no
influence on TAB2 (Fig. 5A). Besides, we found that there was a
short nuclear localization sequence (NLS) at the N-terminal of
RNF4 protein. We expressed truncations of RNF4 together with
TAB2, and found that A-NLS, A-NLS/SIM and RING domain trunca-
tions had more effect on the stability of TAB2 than RNF4 wild type
did (Fig. S2). Consistently, overexpression of wild-type RNF4 and
RNF4-ASIM but not RNF4-C132/135S inhibited TNFa- and IL-1b-
triggered NF-jB activation in reporter assay (Fig. 5C). Previous
study has reported that TAB2 facilitates TAK1 recruitment, and
contributes to NF-jB activation. Then we detected whether ectopic
expression of RNF4 impair TRAF2 interact with TAK1. We express
TRAF2 and TAK1 together with RNF4 or not in HEK293T cells.
The result indicated that ectopic expression of RNF4 impaired
interaction between TRAF2 and TAK1 (Fig. 5B).
In 2008 and 2014, it has been reported respectively by Bing Sun
and Hong-Bing Shu that TAB2 could be destabilized in a
lysosome dependent form [23,24]. To confirm whether RNF4
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B. Tan et al. / FEBS Letters 589 (2015) 2850–2858 2855down-regulate TAB2 through lysosome- or proteasome-dependent
way, we use NH4Cl and MG132 to block each pathway respec-
tively. The result showed that NH4Cl but not MG132 could rescue
RNF4 mediated TAB2 down-regulation and indicated that this kindof destabilization is lysosome-dependent (Fig. 5D). In the endoge-
nous context, it has been reported that TAB2 can be degraded
through lysosome pathway in response to TNFa or IL-1b in 2014.
To address the endogenous role of RNF4 in this TAB2 degradation
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long time-caused TNFa stimulus (Fig. 5E). The result showed that
knockdown of RNF4 could partially rescue TNFa induced TAB2
degradation. Collectively, the results suggested that RNF4 is
involved in lysosomal degradation of TAB2 during the process of
canonical NF-jB activation.
4. Discussion
The transcription factor NF-jB is a critical regulator of diverse
physiological and pathological processes including immune
response, inflammation and cancer development. Manyinflammation-related diseases and cancer are correlated with
excessive NF-jB activation. In order to keep inflammatory home-
ostasis, NF-jB activation process must be tightly controlled. Many
research groups have dedicated time and resources to the study of
regulatory mechanisms in NF-jB signaling pathway. It was
reported that ubiquitination is the key post-translational modifica-
tion in NF-jB pathway and is closely related to the activation of
NF-jB [7,25]. So, we constructed a siRNA library against 203 genes
which contain ubiquitin-related domains to screen regulators of
canonical NF-jB pathway. In this screen, we identified RNF4 which
was used to be called SUMO-targeted ubiquitin ligases as a
negative regulator of NF-jB activation.
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NF-jB activation, whereas overexpression of RNF4 inhibited
TNFa- and IL-lb-induced activation of NF-jB. In similar experi-
ments, overexpression of RNF4 did not have marked effects on poly
I:C-induced activation of IFNb and ISRE. These results suggest that
RNF4 is a specific inhibitor of canonical NF-jB signaling pathways.
Further, RNF4 had obvious effects on TRADD, TRAF2, Myd88, IRAK1and TAK1 – but not IKKb – triggered NF-jB activation. Consis-
tently, overexpression of RNF4 inhibited IKKs and IjBa phosphory-
lation, and impair process of IjBa degradation in response to TNFa
treatment, while knockdown of RNF4 had opposite effects. These
results suggested that RNF4 could act at TAK1 level and inhibit
TAK1 activity to inhibit IKKb phosphorylation and sequentially
IjBa phosphorylation and degradation.
2858 B. Tan et al. / FEBS Letters 589 (2015) 2850–2858To further investigate the mechanism, we use mass spectrome-
try to find interacting proteins of RNF4. Fortunately, we found
TAK1 as a candidate of RNF4 interactors. Co-expression immuno-
precipitation experiment showed that RNF4 can only bind TAK1,
TAB2 and TAB3 but not TAB1. As we know, TAK complex have dif-
ferent compositions under different context. In TGFb pathway,
TAK1 performs its function with TAB1, while in TNFa and IL-1
pathway, TAK1 acts together with TAB2–TAB3. These results indi-
cated that RNF4 has specific role in NF-jB pathway but not TGFb
pathway. Previous studies have elucidated RNF4 function as
down-regulating substrate protein level. We test whether RNF4
may perform similar to NF-jB pathway molecules. The results
showed that ectopic expression of RNF4 could specifically down-
regulate TAB2 level, but not TAK1, TAB1 and so on. Endogenous
immunoprecipitation experiment showed that RNF4 interacted
with TAB2 gradually upon TNFa stimulus. Meanwhile, we found
that the E3 ligase activity of RNF4 was significant to its down-
regulating ability towards TAB2. However, SUMO interacting
ability of RNF4 was dispensable. Consistently, these results were
confirmed by reporter assay. It has been documented that TAB2
facilitates TAK1 recruitment, and contributes to NF-jB activation
[26]. Then we detected that ectopic expression of RNF4 did impair
TRAF2 interact with TAK1. In 2008 and 2014, two independent
groups have discovered that TRIM30a and TRIM38 targeted TAB2
for lysosomal degradation respectively [23,24]. We used protea-
some and lysosome inhibitors, and identified that RNF4 mediated
TAB2 degradation was through lysosome pathway. In endogenous
context, previous study suggested that TAB2 protein level may be
down-regulated upon TNFa stimulus. We found that knockdown
of RNF4 could reverse the down-regulation of TAB2 and make
TAB2 accumulated slightly. As ectopic expression of RNF4 did not
have influence on TAB2 ubiquitination (Data not shown), the
results collectively indicated that RNF4 mediated lysosomal degra-
dation of TAB2 but was a non-direct regulator of TAB2. In the pro-
cess of studying RNF4 sequence, we found that there was a short
nuclear localization sequence (NLS) at the N-terminal of RNF4 pro-
tein. We expressed truncations of RNF4 together with TAB2, and
found that D-NLS, D-NLS/SIM and RING domain truncations had
more effect on the stability of TAB2 than RNF4 wild type did
(Fig. S2). We hypothesis that this phenomenon may be related to
the localization of RNF4.
More experiments are needed in the future to elucidate the
detailed mechanism of RNF4-mediated TAB2 lysosomal degrada-
tion. Taken together, our finding identified a new negative regula-
tor of canonical NF-jB signaling pathway and it may provide a
potential therapeutic target for excessive inflammation.
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